Cheng Yuan, Dong Yangyang, Tian Wenjuan, Zhang Hua, Li Xiaoping, Wang Zhiqi, Shan Boer, Ren Yulan, Wei Lihui, Wang Huaying, Wang Jianliu
Department of Obstetrics and Gynecology, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng Dist., Beijing 100044, China.
Department of Gynecology, Fudan University Shanghai Cancer Center, No. 255, Dong'An Road, Shanghai 200032, China.
J Oncol. 2020 May 29;2020:2363545. doi: 10.1155/2020/2363545. eCollection 2020.
This study aimed at developing an available recurrence-free survival (RFS) model of endometrial cancer (EC) for accurate and individualized prognosis assessment. A training cohort of 520 women with EC who underwent initial surgical treatment and an external validation cohort of 445 eligible EC patients from 2006 to 2016 were analyzed retrospectively. Multivariable Cox proportional hazards regression models were used to develop nomograms for predicting recurrence. The concordance index (C-index) and the area under the receiver operating characteristic curve (AUC) were calculated to determine the discrimination of RFS prognostic scoring systems. Calibration plots were generated to examine the performance characteristics of the predictive nomograms. Regression analysis revealed that an advanced International Federation of Gynecology and Obstetrics (FIGO) stage, histological grade 3, primary tumor diameter ≥2 cm, and positive peritoneal cytology were independent prognostic factors for RFS in EC in the training set. The nomograms estimated RFS according to these four variables, with a C-index of 0.860, which was superior to that of FIGO stage (2009 criteria), at 0.809 (=0.034), in the training cohort. Encouragingly, consistent results were observed in the validation set, with a C-index of 0.875 for the nomogram and a C-index of 0.833 for the FIGO staging (=0.0137). Furthermore, the calibrations of the nomograms predicting 3- and 5-year RFS strongly corresponded to the actual survival outcome. In conclusion, this study developed an available nomogram with effective external validation and relatively appreciable discrimination and conformity for the accurate assessment of 3- and 5-year RFS in Chinese women with EC.
本研究旨在开发一种可用的子宫内膜癌(EC)无复发生存(RFS)模型,用于准确和个体化的预后评估。回顾性分析了2006年至2016年间接受初始手术治疗的520例EC女性训练队列和445例符合条件的EC患者外部验证队列。使用多变量Cox比例风险回归模型开发预测复发的列线图。计算一致性指数(C指数)和受试者操作特征曲线下面积(AUC),以确定RFS预后评分系统的辨别力。生成校准图以检查预测列线图的性能特征。回归分析显示,国际妇产科联盟(FIGO)晚期、组织学3级、原发性肿瘤直径≥2 cm和腹膜细胞学阳性是训练集中EC患者RFS的独立预后因素。列线图根据这四个变量估计RFS,训练队列中C指数为0.860,优于FIGO分期(2009标准)的0.809(=0.034)。令人鼓舞的是,在验证集中观察到了一致的结果,列线图的C指数为0.875,FIGO分期的C指数为0.833(=0.0137)。此外,预测3年和5年RFS的列线图校准与实际生存结果高度一致。总之,本研究开发了一种可用的列线图,具有有效的外部验证以及相对可观的辨别力和一致性,可用于准确评估中国EC女性的3年和5年RFS。